{"component": "definition", "props": {"groups": [{"size": 21, "snippet": "means any indication other than the Initial Indication.", "samples": [{"hash": "3ltQMQOneuT", "uri": "/contracts/3ltQMQOneuT#additional-indication", "label": "Exclusive License and Distribution Agreement (Quoin Pharmaceuticals, Ltd.)", "score": 34.697467804, "published": true}, {"hash": "41yn702R50H", "uri": "/contracts/41yn702R50H#additional-indication", "label": "License and Distribution Agreement (Quoin Pharmaceuticals, Ltd.)", "score": 33.4572219849, "published": true}, {"hash": "fnzAAIWSHPb", "uri": "/contracts/fnzAAIWSHPb#additional-indication", "label": "License and Distribution Agreement (Quoin Pharmaceuticals, Ltd.)", "score": 33.1806983948, "published": true}], "snippet_links": [{"key": "initial-indication", "type": "definition", "offset": [36, 54]}], "hash": "b3e578aa5de3745a68442f3f8f746ec5", "id": 1}, {"size": 12, "snippet": "has the meaning set forth in Section 4.3.1.", "samples": [{"hash": "dh0exlyUbJm", "uri": "/contracts/dh0exlyUbJm#additional-indication", "label": "Development and License Agreement (Onconova Therapeutics, Inc.)", "score": 24.5427780151, "published": true}, {"hash": "dI96LsRkx79", "uri": "/contracts/dI96LsRkx79#additional-indication", "label": "Development and License Agreement (Onconova Therapeutics, Inc.)", "score": 24.4496917725, "published": true}, {"hash": "1SHdi0huJQi", "uri": "/contracts/1SHdi0huJQi#additional-indication", "label": "Development and License Agreement (Onconova Therapeutics, Inc.)", "score": 24.3347015381, "published": true}], "snippet_links": [{"key": "section-431", "type": "clause", "offset": [29, 42]}], "hash": "502ab886039989c85e7153a0606f36ae", "id": 2}, {"size": 9, "snippet": "means, with respect to a particular Licensed Product, an indication for treating or preventing a human disease or condition that is the subject of and covered by a unique NDA application and Regulatory Approval, different from and subsequent to the original Regulatory Approval for such Licensed Product.", "samples": [{"hash": "hx5A0KZZKV5", "uri": "/contracts/hx5A0KZZKV5#additional-indication", "label": "License Agreement", "score": 31.3408622742, "published": true}, {"hash": "wq6kkgT9pT", "uri": "/contracts/wq6kkgT9pT#additional-indication", "label": "License Agreement (Mirna Therapeutics, Inc.)", "score": 26.691991806, "published": true}, {"hash": "2LHmhlKJQrf", "uri": "/contracts/2LHmhlKJQrf#additional-indication", "label": "License Agreement (Mirna Therapeutics, Inc.)", "score": 26.6427097321, "published": true}], "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "licensed-product", "type": "definition", "offset": [36, 52]}, {"key": "subject-of", "type": "clause", "offset": [136, 146]}, {"key": "covered-by", "type": "definition", "offset": [151, 161]}, {"key": "regulatory-approval", "type": "definition", "offset": [191, 210]}, {"key": "the-original", "type": "clause", "offset": [245, 257]}], "hash": "9c7dc32bf7b1c2ffd6d58b4b9db9b291", "id": 3}, {"size": 8, "snippet": "means any Indication for a Product outside of the Field.", "samples": [{"hash": "gGDkDgcq3OF", "uri": "/contracts/gGDkDgcq3OF#additional-indication", "label": "Development, Commercialization and Supply Agreement (Auxilium Pharmaceuticals Inc)", "score": 22.1608486176, "published": true}, {"hash": "lY3qZsZ83Qw", "uri": "/contracts/lY3qZsZ83Qw#additional-indication", "label": "Development and License Agreement (Auxilium Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "lMk05fJeM8c", "uri": "/contracts/lMk05fJeM8c#additional-indication", "label": "Development and License Agreement (Biospecifics Technologies Corp)", "score": 21.0, "published": true}], "snippet_links": [{"key": "outside-of-the-field", "type": "clause", "offset": [35, 55]}], "hash": "c85346505baf3f0a1314dc5627b4cf09", "id": 4}, {"size": 8, "snippet": "means any disease condition, [*****].", "samples": [{"hash": "84KgHjqRqR6", "uri": "/contracts/84KgHjqRqR6#additional-indication", "label": "Research Collaboration and License Agreement (AC Immune SA)", "score": 27.6995201111, "published": true}, {"hash": "jP428uhHxV5", "uri": "/contracts/jP428uhHxV5#additional-indication", "label": "Research Collaboration and License Agreement (AC Immune SA)", "score": 27.4120464325, "published": true}, {"hash": "btHBgzctqz2", "uri": "/contracts/btHBgzctqz2#additional-indication", "label": "Research Collaboration and License Agreement (AC Immune SA)", "score": 26.8945922852, "published": true}], "snippet_links": [], "hash": "ab5ada7ea01f6b6baef73cbc9011e43f", "id": 5}, {"size": 8, "snippet": "means, with respect to the Licensed Compounds and Licensed Products, each indication other than the Initial Indications.", "samples": [{"hash": "8XQXSot3AyX", "uri": "/contracts/8XQXSot3AyX#additional-indication", "label": "Exclusive License Agreement (Ablynx NV)", "score": 28.7508563995, "published": true}, {"hash": "hxGqSiI7F5T", "uri": "/contracts/hxGqSiI7F5T#additional-indication", "label": "Exclusive License Agreement (Ablynx NV)", "score": 28.6605072021, "published": true}, {"hash": "7oTwcsEW75j", "uri": "/contracts/7oTwcsEW75j#additional-indication", "label": "Exclusive License Agreement (Ablynx NV)", "score": 28.6057491302, "published": true}], "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "licensed-compounds-and-licensed-products", "type": "clause", "offset": [27, 67]}, {"key": "initial-indications", "type": "clause", "offset": [100, 119]}], "hash": "079ecd434b8f8716151dc7901192c9d4", "id": 6}, {"size": 5, "snippet": "means each specific cancer indication (other than [\u2026***\u2026]) which Bellicum elects to include in the Licensed Field pursuant to the provisions of Section 2.1.2(a).", "samples": [{"hash": "itQLCfaw3fH", "uri": "/contracts/itQLCfaw3fH#additional-indication", "label": "License Agreement (Bellicum Pharmaceuticals, Inc)", "score": 31.8446273804, "published": true}, {"hash": "cPFYkMcqsDf", "uri": "/contracts/cPFYkMcqsDf#additional-indication", "label": "License Agreement", "score": 31.3408622742, "published": true}, {"hash": "jbjjGlVH3P5", "uri": "/contracts/jbjjGlVH3P5#additional-indication", "label": "License Agreement", "score": 30.4220199585, "published": true}], "snippet_links": [{"key": "cancer-indication", "type": "definition", "offset": [20, 37]}, {"key": "licensed-field", "type": "definition", "offset": [99, 113]}, {"key": "pursuant-to-the-provisions-of-section", "type": "clause", "offset": [114, 151]}], "hash": "d34ff2bf2e82ee9708fe47b11edd9f9f", "id": 7}, {"size": 5, "snippet": "means any disease within the Licensed Field other than the Initial Indication.", "samples": [{"hash": "fvCPxlhYWCu", "uri": "/contracts/fvCPxlhYWCu#additional-indication", "label": "Exclusive Option Agreement (Pieris Pharmaceuticals, Inc.)", "score": 29.3148536682, "published": true}, {"hash": "4IR1QEWtaWq", "uri": "/contracts/4IR1QEWtaWq#additional-indication", "label": "Exclusive Option Agreement (Pieris Pharmaceuticals, Inc.)", "score": 28.3675556183, "published": true}, {"hash": "lFsozgP3RhL", "uri": "http://pdf.secdatabase.com/2648/0001583648-18-000024.pdf", "label": "pdf.secdatabase.com", "score": 20.2548942566, "published": false}], "snippet_links": [{"key": "licensed-field", "type": "definition", "offset": [29, 43]}, {"key": "initial-indication", "type": "definition", "offset": [59, 77]}], "hash": "6975a3197e56645cc44bb432e25e271e", "id": 8}, {"size": 5, "snippet": "has the meaning set forth in Section 2.3.2.", "samples": [{"hash": "7KAmKxcTqHe", "uri": "/contracts/7KAmKxcTqHe#additional-indication", "label": "Master Collaboration Agreement (ArcherDX, Inc.)", "score": 31.4257354736, "published": true}, {"hash": "bBHnduOmR2A", "uri": "/contracts/bBHnduOmR2A#additional-indication", "label": "Master Collaboration Agreement (ArcherDX, Inc.)", "score": 31.3874053955, "published": true}], "snippet_links": [], "hash": "c2a39081c8a1ee59d56e2a597541b16a", "id": 9}, {"size": 4, "snippet": "means, with respect to any Licensed Product, each Licensed Indication other than the Initial Indication with respect to such Licensed Product.", "samples": [{"hash": "fKAKLGdSSR2", "uri": "/contracts/fKAKLGdSSR2#additional-indication", "label": "License Agreement (Reata Pharmaceuticals Inc)", "score": 32.1587944031, "published": true}, {"hash": "5HftZb5eNaE", "uri": "/contracts/5HftZb5eNaE#additional-indication", "label": "License Agreement (Reata Pharmaceuticals Inc)", "score": 26.1026687622, "published": true}, {"hash": "6m3UWG881ng", "uri": "/contracts/6m3UWG881ng#additional-indication", "label": "License Agreement (Reata Pharmaceuticals Inc)", "score": 25.8836421967, "published": true}], "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "licensed-product", "type": "definition", "offset": [27, 43]}, {"key": "licensed-indication", "type": "definition", "offset": [50, 69]}, {"key": "initial-indication", "type": "definition", "offset": [85, 103]}], "hash": "61a2f213ad1194d6eee7bfaaf0b22481", "id": 10}], "next_curs": "CmISXGoVc35sYXdpbnNpZGVyY29udHJhY3Rzcj4LEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIeYWRkaXRpb25hbC1pbmRpY2F0aW9uIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"title": "Additional Indication", "size": 234, "snippet": "means any indication other than the Initial Indication.", "id": "additional-indication", "examples": ["The period during which Auxilium may exercise an <strong>Additional Indication</strong> Option (the \u201cExercise Period\u201d) shall commence on the date on which BTC submits a Phase II Clinical Trial report to Auxilium for the Product for such <strong>Additional Indication</strong> and ends one hundred and twenty (120) days thereafter.", "Auxilium may exercise the <strong>Additional Indication</strong> Option at any time during the Exercise Period by delivering to BTC a written notice of exercise with regard to such <strong>Additional Indication</strong> (each, an \u201cExercised Indication\u201d) that sets forth the effective date of the exercise (the \u201cExercised Indication Date\u201d).", "Subject to the terms and conditions of this Agreement, BTC hereby grants to Auxilium an exclusive option to an exclusive license to Products in the Territory for each <strong>Additional Indication</strong> on the same terms and conditions as provided for Indications in the Field (each, an \u201c<strong>Additional Indication</strong> Option\u201d).", "The Nominated Counsel, acting reasonably, shall advise ALVOTECH if he/she approves or does not approve the draft settlement as satisfactory for the purposes of ALVOTECH confirming Freedom to Launch or <strong>Additional Indication</strong> Freedom to Launch (as applicable) under this Agreement and shall clearly advise in its response as to whether the settlement agreement provides for Freedom to Launch or <strong>Additional Indication</strong> Freedom to Launch (as applicable).", "The appointed Patent Counsel shall then determine if STADA has provided reasonable arguments in declaring its dissatisfaction as to whether there is Freedom to Launch or <strong>Additional Indication</strong> Freedom to Launch (as applicable) or not under the settlement agreement, along with a final determination as to whether the settlement agreement provides for Freedom to Launch or <strong>Additional Indication</strong> Freedom to Launch (as applicable).", "Without limitation of ALVOTECH\u2019s responsibility (as stated in this Article 11.4) for Freedom to Launch and, if required pursuant to Article 11.3, <strong>Additional Indication</strong> Freedom to Launch, the Parties will discuss issues relating to Third Party Patents in order to try and reach an agreed opinion as to when it is reasonable to Launch the Products without incurring a material risk of a successful infringement challenge under any Third Party Patent.", "The Nominated Counsel will be retained, and paid for, by ALVOTECH as a second or alternative legal counsel and will be instructed by ALVOTECH with a copy to STADA that his/her review covers only (i) the key question whether the settlement agreement provides for Freedom to Launch or <strong>Additional Indication</strong> Freedom to Launch (as applicable) and (ii) how to redraft the draft settlement agreement in order to achieve such Freedom To Launch or <strong>Additional Indication</strong> Freedom to Launch (as applicable).", "STADA, acting entirely at its own discretion, shall decide that it approves or does not approve the draft settlement as satisfactory for the purposes of ALVOTECH confirming Freedom to Launch or <strong>Additional Indication</strong> Freedom to Launch (if applicable).", "ALVOTECH shall keep STADA informed as to its progress in obtaining such <strong>Additional Indication</strong> Freedom to Launch.", "The JCC will establish the detail level, detail position, promotion message, promotion materials and additional promotional matters for each <strong>Additional Indication</strong> consistent with the terms of this Agreement."], "related": [["initial-indication", "Initial Indication", "Initial Indication"], ["additional-sdu-study", "Additional SDU Study", "Additional SDU Study"], ["additional-product", "Additional Product", "Additional Product"], ["collaboration-product", "Collaboration Product", "Collaboration Product"], ["geographical-indication", "geographical indication", "geographical indication"]], "related_snippets": [], "updated": "2026-02-21T05:44:01+00:00"}, "json": true, "cursor": ""}}